3 Healthcare Stock Stories For Tuesday Investment Wellness

 Cubist Pharmaceuticals (NASDAQ: CBST): Closing price $47.63

On Tuesday, Cubist said that the FDA awarded its late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously-granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. The FDA granted Fast Track status for ceftolozane/tazobactam in Complicated Intra-Abdominal Infections back in February.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CBST

Raptor Pharmaceutical Corp. (NASDAQ:RPTP): Closing price $6.17

The corporation has licensed pending patents linked to the use of cysteamine for the treatment of Rett syndrome and allied disorders of methyl-CpG binding protein 2 (MECP2). Through the terms, Raptor receives exclusive world rights to develop and commercialize cysteamine and related compounds in the treatment of MECP2-associated disorders. Raptor’s license agreement was made with the Technology Transfer Accelerator of South Eastern France which represents the French medical research organizations where the technology was invented, including the Institut Curie, INSERM, and Aix-Marseille Université.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

RPTP

GW Pharmaceuticals (NASDAQ: GWPH): Closing price $8.91

GW has received commercialization clearance in Italy for its prescription medicine Sativex. A full marketing authorization has been bestowed by the authorities there for the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded sufficiently to other anti-spasticity medications. GW is a biopharmaceutical firm concentrated upon discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GWPH

Don’t Miss: Is Molycorp Showing Signs of Life?

More from The Cheat Sheet